|
|
HHSN292201500060U
|
$5,878,180
|
N/A
|
CONSTELLATION NEW ENERGY
|
|
(10.) The Gut Microbiome and Responses to Neoadjuvant Chemoradiation in Rectal Cancer Patients
|
5R21CA205636-02
|
$202,275
|
CHEN, GRACE
|
UNIVERSITY OF MICHIGAN
|
|
(NSF: 2018 GENERAL SOCIAL SURV) ADDING GLOBAL HEALTH ITEMS TO THE 2018 GENERAL SOCIAL SURVEY
|
APC17004
|
$187,328
|
UNKNOWN, UNKNOWN
|
NATIONAL SCIENCE FOUNDATION
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
5R01CA206025-02
|
$637,172
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation
|
5R01CA206026-02
|
$356,850
|
WALDMAN, SCOTT
|
THOMAS JEFFERSON UNIVERSITY
|
|
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy
|
5R21CA205644-02
|
$202,439
|
WHITESIDE, THERESA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
(PQ2) HIV INFECTION, APOBEC UPREGULATION, AND CANCER MUTAGENESIS
|
5R21CA206309-02
|
$182,192
|
HARRIS, REUBEN
|
UNIVERSITY OF MINNESOTA
|
|
(PQ3) Immune Modulation of DNA Mismatch Repair in Colorectal Cancer
|
5R01CA206010-02
|
$369,639
|
CARETHERS, JOHN
|
UNIVERSITY OF MICHIGAN
|
|
(PQ4A) Metabolic Plasticity of Pre-Malignant Cells During Tumor Progression
|
5R01CA194461-03
|
$334,552
|
PARK, KWON-SIK
|
UNIVERSITY OF VIRGINIA
|
|
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
|
5R01CA205967-02
|
$386,588
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INST
|
|
(PQ5) Mitochondria are endocellular symbionts that serve as targets for immune recognition
|
5R01CA206012-02
|
$402,548
|
FACCIABENE, ANDREA
|
UNIVERSITY OF PENNSYLVANIA
|
|
(PQ5) Role of Mitochondrial Division in Cancer Biology
|
5R01CA206005-02
|
$351,209
|
CHIPUK, JERRY
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
(PQ6) Molecular Mechanisms Driving Benign to Malignant Transitions in Breast Cancer
|
5R01CA205632-02
|
$457,974
|
RIEGEL, ANNA
|
GEORGETOWN UNIVERSITY
|
|
(PQ7) In Vivo Cellular Optical Imaging of Esophageal Tumors and Microenvironment
|
5R01CA205431-02
|
$529,795
|
PERELMAN, LEV
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy
|
5R01CA206028-02
|
$342,964
|
GEWIRTZ, DAVID
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle
|
5R21CA205437-03
|
$168,236
|
WANING, DAVID
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
(PQ9) The role of Bclw (bcl2l2) in preventing chemotherapy induced neuropathy
|
5R01CA205255-02
|
$577,463
|
SEGAL, ROSALIND
|
DANA-FARBER CANCER INST
|
|
(PQA1) The antipsychotic thioridazine protects against medulloblastoma (MB): volu
|
5R01CA185039-04
|
$373,436
|
JAN, LILY
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQA2) Interstitial stiffness as a physicochemical modulator of obesity-induced b
|
5R01CA185293-04
|
$329,104
|
FISCHBACH, CLAUDIA
|
CORNELL UNIVERSITY
|
|
(PQA2): Escape from breast tumor dormancy: convergence of obesity and menopause
|
5R01CA185530-04
|
$367,275
|
MOSES, MARSHA
|
BOSTON CHILDREN'S HOSPITAL
|
|
(PQA4) Molecularly Targeted Chemoprevention for Preneoplastic Squamous (5R01 CA194617-02)
|
5R01CA194617-04
|
$412,607
|
TSAI, KENNETH
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
(PQA5) 'Dose and Mechanisms of Exercise in Breast Cancer Prevention'
|
5R01CA179992-04
|
$909,181
|
JONES, LEE
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
(PQB-2) "Driver" vs. "passenger" epigenetic events in Ewing sarcoma
|
5R01CA183776-05
|
$309,175
|
LESSNICK, STEPHEN
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
|
(PQB-3) Driver gene-induced inflammation in pancreatic cancer development
|
5R01CA184926-04
|
$765,544
|
JAFFEE, ELIZABETH
|
JOHNS HOPKINS UNIVERSITY
|
|
(PQB-4) Opposing Effects of the SASP in Cancer Progression
|
5R01CA184572-04
|
$329,925
|
HERBIG, UTZ
|
RBHS-NEW JERSEY MEDICAL SCHOOL
|
|
(PQB3) CD4 T cell response to BCR-ABL-positive Leukemia
|
5R01CA185062-04
|
$312,304
|
FARRAR, MICHAEL
|
UNIVERSITY OF MINNESOTA
|
|
(PQB3) Investigating innate immunosurveillance of oncogene-induced danger signals
|
5R01CA185020-04
|
$325,181
|
JACKS, TYLER
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
(PQB4) Stochastic Profiling of Functional Single-Cell States Within Solid Tumors
|
5R01CA194470-03
|
$446,627
|
JANES, KEVIN
|
UNIVERSITY OF VIRGINIA
|
|
(PQB5) Reconstruction of Evolutionary Networks using Cross-Sectional Genomic Data
|
5R01CA185486-04
|
$517,690
|
RABADAN, RAUL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
(PQB5)Molecular Wiring and Therapeutic Targeting of EGFR and PDGFR Signaling Netw
|
5R01CA185137-04
|
$882,372
|
CHAREST, ALAIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
(PQC1) Accelerated biological aging and colon polyp to cancer progression
|
5R01CA194663-03
|
$401,482
|
GRADY, WILLIAM
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
(PQC2) Localization as a determinant of cancer dormancy
|
5R01CA194596-03
|
$553,740
|
LIN, CHARLES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
(PQC2)Nanoscale changes in 3D nuclear architecture during breast tumorigenesis
|
5R01CA185363-04
|
$318,250
|
LIU, YANG
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
(PQC6) Molecular Determinants of Quiescent Cancer Cells
|
5R01CA185086-04
|
$423,327
|
VASUDEVAN, SHOBHA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
(PQD-5) Patient derived orthotopic xenograft models for drug response prediction
|
5R01CA185402-04
|
$318,923
|
LI, XIONAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
|
5R01CA185151-04
|
$613,546
|
NOVINA, CARL
|
DANA-FARBER CANCER INST
|
|
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL
|
5R01CA184922-04
|
$553,684
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
(PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers
|
5R01CA184968-04
|
$509,161
|
SIKIC, BRANIMIR
|
STANFORD UNIVERSITY
|
|
(PQD3) Mechanisms of prolonged initial disease-free survival in glioblastoma
|
5R01CA184320-04
|
$738,276
|
SARKARIA, JANN
|
MAYO CLINIC ROCHESTER
|
|
(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer
|
5R01CA185357-04
|
$398,393
|
AHUJA, NITA
|
JOHNS HOPKINS UNIVERSITY
|
|
(PQD5) A novel genetic strategy to predict efficacy of anti-CD20 antibodies
|
5R01CA185372-04
|
$321,625
|
RICHARDS, KRISTY
|
CORNELL UNIVERSITY
|
|
(PQD5) Avatar-directed Treatment for Ovarian Cancer
|
5R01CA184502-04
|
$714,297
|
WEROHA, SARAVUT
|
MAYO CLINIC ROCHESTER
|
|
(PQD5) imaging systemic tissue injuries induced by anticancer drugs
|
5R01CA185214-04
|
$496,930
|
ZHAO, MING
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
(PQD5) Predicting Anti-Cancer Efficacy through Tumor Profiling
|
5R01CA185353-04
|
$405,890
|
KIM, WILLIAM
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
01/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048377-24
|
$39,000
|
GADDE, KISHORE
|
LSU PENNINGTON BIOMEDICAL RESEARCH CTR
|
|
02/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048381-24
|
$68,181
|
EHRMANN, DAVID
|
UNIVERSITY OF CHICAGO
|
|
03/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048468-24
|
$68,181
|
Furlong, Kevin
|
THOMAS JEFFERSON UNIVERSITY
|
|
04/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048434-24
|
$68,181
|
Goldberg, Ronald
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
05/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Proj
|
U01DK048514-24
|
$68,181
|
HAZUDA, HELEN
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|